Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
248.43
+4.96 (2.04%)
At close: Feb 27, 2026, 4:00 PM EST
248.51
+0.08 (0.03%)
After-hours: Feb 27, 2026, 7:59 PM EST
Johnson & Johnson Employees
Johnson & Johnson had 138,200 employees as of December 31, 2025. The number of employees increased by 100 or 0.07% compared to the previous year.
Employees
138,200
Change (1Y)
100
Growth (1Y)
0.07%
Revenue / Employee
$681,570
Profits / Employee
$193,951
Market Cap
598.69B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 138,200 | 100 | 0.07% |
| Dec 31, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Dec 31, 2022 | 152,700 | 11,000 | 7.76% |
| Dec 31, 2021 | 141,700 | 7,200 | 5.35% |
| Dec 31, 2020 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | 132,200 | -2,900 | -2.15% |
| Dec 30, 2018 | 135,100 | 1,100 | 0.82% |
| Dec 31, 2017 | 134,000 | 7,600 | 6.01% |
| Dec 31, 2016 | 126,400 | -700 | -0.55% |
| Dec 31, 2015 | 127,100 | 600 | 0.47% |
| Dec 28, 2014 | 126,500 | -1,600 | -1.25% |
| Dec 29, 2013 | 128,100 | 500 | 0.39% |
| Dec 30, 2012 | 127,600 | 9,700 | 8.23% |
| Dec 31, 2011 | 117,900 | 3,900 | 3.42% |
| Dec 31, 2010 | 114,000 | -1,500 | -1.30% |
| Dec 31, 2009 | 115,500 | -3,200 | -2.70% |
| Dec 28, 2008 | 118,700 | -500 | -0.42% |
| Dec 30, 2007 | 119,200 | -3,000 | -2.45% |
| Dec 31, 2006 | 122,200 | 6,600 | 5.71% |
| Dec 31, 2005 | 115,600 | 5,600 | 5.09% |
| Dec 31, 2004 | 110,000 | -1,000 | -0.90% |
| Dec 28, 2003 | 111,000 | 3,000 | 2.78% |
| Dec 29, 2002 | 108,000 | 6,000 | 5.88% |
| Dec 30, 2001 | 102,000 | 1,000 | 0.99% |
| Dec 31, 2000 | 101,000 | 3,200 | 3.27% |
| Dec 31, 1999 | 97,800 | 4,700 | 5.05% |
| Dec 31, 1998 | 93,100 | 2,600 | 2.87% |
| Dec 28, 1997 | 90,500 | 1,200 | 1.34% |
| Dec 29, 1996 | 89,300 | 7,000 | 8.51% |
| Dec 31, 1995 | 82,300 | 800 | 0.98% |
| Dec 31, 1994 | 81,500 | -100 | -0.12% |
| Dec 31, 1993 | 81,600 | -3,300 | -3.89% |
| Dec 31, 1992 | 84,900 | 2,200 | 2.66% |
| Dec 31, 1991 | 82,700 | 500 | 0.61% |
| Dec 31, 1990 | 82,200 | -900 | -1.08% |
| Dec 31, 1989 | 83,100 | 1,800 | 2.21% |
| Dec 31, 1988 | 81,300 | 3,100 | 3.96% |
| Dec 31, 1987 | 78,200 | 1,100 | 1.43% |
| Dec 31, 1986 | 77,100 | 2,200 | 2.94% |
| Dec 31, 1985 | 74,900 | 700 | 0.94% |
| Dec 31, 1984 | 74,200 | -3,200 | -4.13% |
| Dec 31, 1983 | 77,400 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 92,900 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
JNJ News
- 1 day ago - Best Dividend Aristocrats For March 2026 - Seeking Alpha
- 1 day ago - 2 Dividend Kings That Could Easily Keep The Growth Streak Alive - Seeking Alpha
- 2 days ago - Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer - PRNewsWire
- 4 days ago - Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) - PRNewsWire
- 5 days ago - Does JNJ Stock Still Offer Value? - Forbes
- 5 days ago - Bayer files lawsuit against Johnson & Johnson, Janssen Biotech - Reuters
- 5 days ago - Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA - Business Wire
- 7 days ago - TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years - PRNewsWire